The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery

Kotaro Yamamoto, Taiki Kokubun, Kota Sato, Takahiro Akaishi, Atsushi Shimazaki, Masatsugu Nakamura, Yukihiro Shiga, Satoru Tsuda, Kazuko Omodaka, Hideyuki Saya, Toru Nakazawa

Research output: Contribution to journalArticle

Abstract

Treatments for refractory glaucoma include trabeculectomy, in which a filtering bleb is created to reduce aqueous pressure. Mitomycin C (MMC) is often used as an adjuvant to reduce post-trabeculectomy bleb scarring and consequent failure. However, scarring sometimes still occurs. Thus, we searched for more effective trabeculectomy adjuvants with high-throughput screening (HTS) of a library of 1,165 off-patent drug compounds. This revealed that amsacrine (AMSA), a DNA topoisomerase II (TOP2) inhibitor, was the top candidate. Compared to MMC, rabbits that underwent trabeculectomy with 10% AMSA had lower IOP at 42, 56, and 70 days (P < 0.01 at all measurement points) and a higher bleb score at 28, 42, 56, and 70 days (P = < 0.01, 0.04, 0.04, and < 0.01, respectively). Compared to saline, rabbits that received 1% AMSA also had lower IOP and better bleb score at all time points, without a sharp drop in IOP just after surgery (all P < 0.01). Both effects were milder than MMC at 7 days (P = 0.02 and <0.01, respectively). Thus, this study showed that HTS may help identify new, promising uses for off-patent drugs. Furthermore, trabeculectomy with AMSA at a suitable concentration may improve the prognosis after trabeculectomy compared to MMC.

Original languageEnglish
Article number19288
JournalScientific reports
Volume9
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Amsacrine
Filtering Surgery
Topoisomerase II Inhibitors
Trabeculectomy
Glaucoma
Mitomycin
Blister
Cicatrix
Rabbits
Patents
Pharmaceutical Preparations
Pressure

ASJC Scopus subject areas

  • General

Cite this

Yamamoto, K., Kokubun, T., Sato, K., Akaishi, T., Shimazaki, A., Nakamura, M., ... Nakazawa, T. (2019). The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery. Scientific reports, 9(1), [19288]. https://doi.org/10.1038/s41598-019-55365-7

The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery. / Yamamoto, Kotaro; Kokubun, Taiki; Sato, Kota; Akaishi, Takahiro; Shimazaki, Atsushi; Nakamura, Masatsugu; Shiga, Yukihiro; Tsuda, Satoru; Omodaka, Kazuko; Saya, Hideyuki; Nakazawa, Toru.

In: Scientific reports, Vol. 9, No. 1, 19288, 01.12.2019.

Research output: Contribution to journalArticle

Yamamoto, K, Kokubun, T, Sato, K, Akaishi, T, Shimazaki, A, Nakamura, M, Shiga, Y, Tsuda, S, Omodaka, K, Saya, H & Nakazawa, T 2019, 'The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery', Scientific reports, vol. 9, no. 1, 19288. https://doi.org/10.1038/s41598-019-55365-7
Yamamoto, Kotaro ; Kokubun, Taiki ; Sato, Kota ; Akaishi, Takahiro ; Shimazaki, Atsushi ; Nakamura, Masatsugu ; Shiga, Yukihiro ; Tsuda, Satoru ; Omodaka, Kazuko ; Saya, Hideyuki ; Nakazawa, Toru. / The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{d1755e8f4056454092c0ab800a24309e,
title = "The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery",
abstract = "Treatments for refractory glaucoma include trabeculectomy, in which a filtering bleb is created to reduce aqueous pressure. Mitomycin C (MMC) is often used as an adjuvant to reduce post-trabeculectomy bleb scarring and consequent failure. However, scarring sometimes still occurs. Thus, we searched for more effective trabeculectomy adjuvants with high-throughput screening (HTS) of a library of 1,165 off-patent drug compounds. This revealed that amsacrine (AMSA), a DNA topoisomerase II (TOP2) inhibitor, was the top candidate. Compared to MMC, rabbits that underwent trabeculectomy with 10{\%} AMSA had lower IOP at 42, 56, and 70 days (P < 0.01 at all measurement points) and a higher bleb score at 28, 42, 56, and 70 days (P = < 0.01, 0.04, 0.04, and < 0.01, respectively). Compared to saline, rabbits that received 1{\%} AMSA also had lower IOP and better bleb score at all time points, without a sharp drop in IOP just after surgery (all P < 0.01). Both effects were milder than MMC at 7 days (P = 0.02 and <0.01, respectively). Thus, this study showed that HTS may help identify new, promising uses for off-patent drugs. Furthermore, trabeculectomy with AMSA at a suitable concentration may improve the prognosis after trabeculectomy compared to MMC.",
author = "Kotaro Yamamoto and Taiki Kokubun and Kota Sato and Takahiro Akaishi and Atsushi Shimazaki and Masatsugu Nakamura and Yukihiro Shiga and Satoru Tsuda and Kazuko Omodaka and Hideyuki Saya and Toru Nakazawa",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-55365-7",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery

AU - Yamamoto, Kotaro

AU - Kokubun, Taiki

AU - Sato, Kota

AU - Akaishi, Takahiro

AU - Shimazaki, Atsushi

AU - Nakamura, Masatsugu

AU - Shiga, Yukihiro

AU - Tsuda, Satoru

AU - Omodaka, Kazuko

AU - Saya, Hideyuki

AU - Nakazawa, Toru

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Treatments for refractory glaucoma include trabeculectomy, in which a filtering bleb is created to reduce aqueous pressure. Mitomycin C (MMC) is often used as an adjuvant to reduce post-trabeculectomy bleb scarring and consequent failure. However, scarring sometimes still occurs. Thus, we searched for more effective trabeculectomy adjuvants with high-throughput screening (HTS) of a library of 1,165 off-patent drug compounds. This revealed that amsacrine (AMSA), a DNA topoisomerase II (TOP2) inhibitor, was the top candidate. Compared to MMC, rabbits that underwent trabeculectomy with 10% AMSA had lower IOP at 42, 56, and 70 days (P < 0.01 at all measurement points) and a higher bleb score at 28, 42, 56, and 70 days (P = < 0.01, 0.04, 0.04, and < 0.01, respectively). Compared to saline, rabbits that received 1% AMSA also had lower IOP and better bleb score at all time points, without a sharp drop in IOP just after surgery (all P < 0.01). Both effects were milder than MMC at 7 days (P = 0.02 and <0.01, respectively). Thus, this study showed that HTS may help identify new, promising uses for off-patent drugs. Furthermore, trabeculectomy with AMSA at a suitable concentration may improve the prognosis after trabeculectomy compared to MMC.

AB - Treatments for refractory glaucoma include trabeculectomy, in which a filtering bleb is created to reduce aqueous pressure. Mitomycin C (MMC) is often used as an adjuvant to reduce post-trabeculectomy bleb scarring and consequent failure. However, scarring sometimes still occurs. Thus, we searched for more effective trabeculectomy adjuvants with high-throughput screening (HTS) of a library of 1,165 off-patent drug compounds. This revealed that amsacrine (AMSA), a DNA topoisomerase II (TOP2) inhibitor, was the top candidate. Compared to MMC, rabbits that underwent trabeculectomy with 10% AMSA had lower IOP at 42, 56, and 70 days (P < 0.01 at all measurement points) and a higher bleb score at 28, 42, 56, and 70 days (P = < 0.01, 0.04, 0.04, and < 0.01, respectively). Compared to saline, rabbits that received 1% AMSA also had lower IOP and better bleb score at all time points, without a sharp drop in IOP just after surgery (all P < 0.01). Both effects were milder than MMC at 7 days (P = 0.02 and <0.01, respectively). Thus, this study showed that HTS may help identify new, promising uses for off-patent drugs. Furthermore, trabeculectomy with AMSA at a suitable concentration may improve the prognosis after trabeculectomy compared to MMC.

UR - http://www.scopus.com/inward/record.url?scp=85076552675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076552675&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-55365-7

DO - 10.1038/s41598-019-55365-7

M3 - Article

C2 - 31848363

AN - SCOPUS:85076552675

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 19288

ER -